---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-076471"
form_type: "8-K"
ticker: "EQ"
cik: "0001746466"
company_name: "Equillium, Inc."
filed_at: "2024-03-25T23:59:59+00:00"
generated_at: "2026-06-04T08:33:30.181459+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Equillium reports $40.9M cash; EQ101 Phase 2 topline due Q2; Ono itolizumab option decision 2H 2024

## Summary
- Cash $40.9M at Dec 31, 2023; runway into 2H 2025.
- EQ101 Phase 2 alopecia areata enrollment complete; topline data Q2 2024.
- FY2023 revenue $36.1M (Ono partnership); net loss $13.3M vs $62.4M prior year.
- Ono option exercise for itolizumab expected 2H 2024; $33M exercise payment plus $101M milestones.
- Phase 3 EQUATOR aGVHD interim review expected Q3 2024.

## SEC filing metadata
- accession: 0001193125-24-076471
- form_type: 8-K
- ticker: EQ
- cik: 0001746466
- company_name: Equillium, Inc.
- filed_at: 2024-03-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746466/000119312524076471/0001193125-24-076471-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746466/000119312524076471/d813838d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-076471
- JSON: https://secwatch.observer/filing/0001193125-24-076471.json
- Plain text: https://secwatch.observer/filing/0001193125-24-076471.txt

## Key facts
- Earnings Releases
  Equillium, Inc. reported the fourth quarter and full year 2023 results: revenue $9.2 million.
  - Period: the fourth quarter and full year 2023
  - Revenue: $9.2 million
  - Result: reported results
  source text: Revenue for the fourth quarter of 2023 was $9.2 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1746466/000119312524076471/0001193125-24-076471-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.